Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

FINGOLIMOD NEURAXPHARM 0,5 MG CAPSULAS DURAS EFG - CIMA-AEMPS Drug Approval Details

Approvals/CIMA-AEMPS/FINGOLIMOD NEURAXPHARM 0,5 MG CAPSULAS DURAS EFG

Approved

STANDARD

FINGOLIMOD NEURAXPHARM 0,5 MG CAPSULAS DURAS EFG

Neuraxpharm Spain S.L.🇪🇸 Spanish Agency of Medicines and Medical Devices

Approval Date: Mar 20, 2021
Approval ID: d9ca59d50f29dd91
Company: Neuraxpharm Spain S.L.
Type: Standard

Approval Details

Approval Id: d9ca59d50f29dd91
Drug Cima Aemps Name: FINGOLIMOD NEURAXPHARM 0,5 MG CAPSULAS DURAS EFG
Register Number: 85855
Holder Company Name: Neuraxpharm Spain S.L.
Marketing Company Name: Neuraxpharm Spain S.L.
Authorization Date: 2021-03-20
Dosage Form: CÁPSULA DURA
Dose: 0,5 mg
Route Of Administration: VÍA ORAL
Prescription Type: Uso Hospitalario
Commercialized: No
Company Name: Neuraxpharm Spain S.L.

Approved

Quick Info

Agency

CIMA-AEMPS

Country

🇪🇸

Approval Date

Mar 20, 2021

Approval ID

d9ca59d50f29dd91

Type

Standard

Back to CIMA-AEMPS Approvals